secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2024-07-12T23:59:59+00:00
Accession:  0001104659-24-079601
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics receives Nasdaq MVLS deficiency notice; must regain compliance by Jan 7, 2025
--------------------------------------------------------------------------------

- Nasdaq notified Gain on June 11, 2024, that MVLS was below $50M minimum required for Global Market listing.
- Company has 180 days (through Jan 7, 2025) to achieve MVLS >= $50M for ten consecutive business days.
- Failure to comply may lead to delisting; company could appeal or apply to transfer to Nasdaq Capital Market.
- Gain intends to monitor and take reasonable measures but cannot assure compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465924079601/0001104659-24-079601-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465924079601/tm2419326d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-079601

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer